Analysed QUANTUM BIOPHARMA-B SUB VOT (QNTM:NASDAQ) News Sources
Quantum BioPharma (QNTM) Executive Outlines Lucid-MS Development Strategy and Commercial Growth Plans
28-07-2026
yahoo.com
Quantum BioPharma (QNTM) Advances MS Imaging Study With Encouraging Preliminary Results
03-08-2026
yahoo.com
Quantum BioPharma (QNTM) Receives FDA Clearance to Advance Lucid-MS Into Phase 2
10-08-2026
yahoo.com
EXCLUSIVE: Quantum BioPharma Achieves Major Milestone With FDA Clearance for Multiple Sclerosis Trial
12-08-2026
yahoo.com
Quantum BioPharma (QNTM) Targets Disability Drivers Beyond Relapse Rates in Multiple Sclerosis
13-08-2026
yahoo.com
Quantum BioPharma Strengthens Equity and Liquidity in Q2 2026 as FDA Approves Lucid-MS for Pivotal Phase 2 Clinical Trial
14-08-2026
yahoo.com
Quantum BioPharma (QNTM) Reports Lower Q2 Expenses, Advances Lucid-MS Into Phase 2
17-08-2026
yahoo.com
Quantum BioPharma (QNTM) Advances Myelin-Protecting MS Therapy as Treatment Paradigm Evolves
20-08-2026
yahoo.com
What is the current price of QUANTUM BIOPHARMA-B SUB VOT (QNTM:NASDAQ)?
The current price of QUANTUM BIOPHARMA-B SUB VOT (QNTM:NASDAQ) is $3.075.
QUANTUM BIOPHARMA-B SUB VOT (QNTM:NASDAQ) absolute price change since previous trading day?
The absolute price change of QUANTUM BIOPHARMA-B SUB VOT (QNTM:NASDAQ) since the previous trading day is $-0.055.
QUANTUM BIOPHARMA-B SUB VOT (QNTM:NASDAQ) percentage price change since previous trading day?
The percentage price change of QUANTUM BIOPHARMA-B SUB VOT (QNTM:NASDAQ) since the previous trading day is -1.7572%.
What is the most recent average sentiment score for QUANTUM BIOPHARMA-B SUB VOT (QNTM:NASDAQ)?
The most recent average sentiment score for QUANTUM BIOPHARMA-B SUB VOT (QNTM:NASDAQ) is 75 out of 100.
What is the most recent average sentiment for QUANTUM BIOPHARMA-B SUB VOT (QNTM:NASDAQ)?
The most recent sentiment for QUANTUM BIOPHARMA-B SUB VOT (QNTM:NASDAQ) is .
SEC-8K** Filing Available For QUANTUM BIOPHARMA-B SUB VOT (QNTM:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.